Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Private versus public hospital care after emergency admission for atrial fibrillation: a call for optimising atrial fibrillation care.

Heart (British Cardiac Society)·2026
Same author

The Harrowing Status of Research and Medical Practice in Countries Affected by War.

European cardiology·2026
Same author

Interactions of blood biomolecules with early rhythm control in atrial fibrillation patients: Exploratory analysis of the EAST-AFNET 4 Biomolecule Study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Edoxaban for Stroke Prevention in Atrial Fibrillation in Spain and Portugal: 4-Year Follow-Up of the Observational ETNA-AF-Europe Study.

Journal of clinical medicine·2026
Same author

Early complications and long-term outcome of patients treated with a Subcutaneous Cardioverter-Defibrillator: temporal trends and clinical implications of the anesthetic strategies adopted at implant.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Analgosedation for catheter ablation in deep sedation: comparison between cryoballoon and pulsed field ablation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026

関連する実験動画

Updated: Sep 9, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

デバイスで検出された心房細動と多発性脳卒中リスク因子の患者における抗凝固薬の効果: NOAH- AFNET 6試験の勝率分析

Nina Becher1,2, Gina Köllner3,4, Emanuele Bertaglia5

  • 1Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany.

European heart journal. Quality of care & clinical outcomes
|September 1, 2025
PubMed
まとめ

器具で検出された心房細動 (DDAF) の患者では,抗凝固薬がない患者に対してエドキサバンが有意な利点を示さなかった. 死亡率と重度の出血の割合は同じでした.

キーワード:
装置で検出された心房細動大きな出血NOAH-AFNET 6 について口服抗凝固剤脳卒中のリスクウィン比率

さらに関連する動画

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.8K

関連する実験動画

Last Updated: Sep 9, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.8K

科学分野:

  • 心臓病科
  • 薬理学について
  • 臨床試験

背景:

  • 器具で検出された心房細動 (DDAF) の患者は,ECGで診断された心房細動 (AF) の患者と比較して,脳卒中のリスクが低い.
  • DDAFにおける口服抗凝固剤の決定は,脳卒中予防の潜在的な利益と,血出の固有のリスクとの間の慎重なバランスを要求する.

研究 の 目的:

  • エドキサバンの有効性と安全性を評価する.
  • 死亡,脳卒中,全身栓塞,心筋梗塞,重度の出血を評価する.

主な方法:

  • NOAH- AFNET 6試験のデータセットで勝率分析が行われました.
  • 主要な分析は,あらゆる原因による死亡,脳卒中,全身/肺栓塞/心筋梗塞,大出血を階層的に順序付けました.
  • 追加の分析では,心血管疾患による死亡と患者の報告したアウトカムが含まれており,未決定の比較では勝率が計算された.

主要な成果:

  • エドキサバンを抗凝固剤なしと比較した勝利比率は0. 87 (95%CI: 0. 68- 1. 10; P = 0. 23) で,有意な差異は示されなかった.
  • エドキサバンは46%,プラセボは54%の確率で勝った.
  • 死と大きな出血は,試験で観察された最も頻繁な出来事でした.

結論:

  • この勝利比分析は,DDAF患者の抗凝固療法に対するエドキサバンの利点を示さない.
  • この研究では,命の質を考慮して,あるいは考慮せずに,血栓性イベント,死亡,出血を統合した.
  • 死と大きな出血が最も一般的な有害事象として特定されました.